Daniel Janney, Director, 10% Owner at Esperion Therapeutics, Inc. (ESPR), bought 500,000 shares at $20.00 ($10.0M) on 2014-10-21, disclosed to the SEC on 2014-10-21.
Open-market purchase of $10.0M ESPR by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| KRYS | SELL | 2023-06-09 | $8.3M | — | Filing → |
| KRYS | SELL | 2023-05-23 | $4.8M | — | Filing → |
| KRYS | SELL | 2023-05-11 | $1.6M | — | Filing → |